Aminoguanidine reduces diabetes‑associated cardiac fibrosis

  • Authors:
    • Fernando Magdaleno
    • Chuck Christopher Blajszczak
    • Claudia Lisette Charles‑Niño
    • Alma Marlene Guadrón‑Llanos
    • Alan Omar Vázquez‑Álvarez
    • Alejandra Guillermina Miranda‑Díaz
    • Natalia Nieto
    • María Cristina Islas‑Carbajal
    • Ana Rosa Rincón‑Sánchez
  • View Affiliations

  • Published online on: August 20, 2019     https://doi.org/10.3892/etm.2019.7921
  • Pages: 3125-3138
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aminoguanidine (AG) inhibits advanced glycation end products (AGEs) and advanced oxidation protein products (AOPP) accumulated as a result of excessive oxidative stress in diabetes. However, the molecular mechanism by which AG reduces AGE‑associated damage in diabetes is not well understood. Thus, we investigated whether AG supplementation mitigates oxidative‑associated cardiac fibrosis in rats with type 2 diabetes mellitus (T2DM). Forty‑five male Wistar rats were divided into three groups: Control, T2DM and T2DM+AG. Rats were fed with a high‑fat, high‑carbohydrate diet (HFCD) for 2 weeks and rendered diabetic using low‑dose streptozotocin (STZ) (20 mg/kg), and one group was treated with AG (20 mg/kg) up to 25 weeks. In vitro experiments were performed in primary rat myofibroblasts to confirm the antioxidant and antifibrotic effects of AG and to determine if blocking the receptor for AGEs (RAGE) prevents the fibrogenic response in myofibroblasts. Diabetic rats exhibited an increase in cardiac fibrosis resulting from HFCD and STZ injections. By contrast, AG treatment significantly reduced cardiac fibrosis, α‑smooth muscle actin (αSMA) and oxidative‑associated Nox4 and Nos2 mRNA expression. In vitro challenge of myofibroblasts with AG under T2DM conditions reduced intra‑ and extracellular collagen type I expression and Pdgfb, Tgfβ1 and Col1a1 mRNAs, albeit with similar expression of Tnfα and Il6 mRNAs. This was accompanied by reduced phosphorylation of ERK1/2 and SMAD2/3 but not of AKT1/2/3 and STAT pathways. RAGE blockade further attenuated collagen type I expression in AG‑treated myofibroblasts. Thus, AG reduces oxidative stress‑associated cardiac fibrosis by reducing pERK1/2, pSMAD2/3 and collagen type I expression via AGE/RAGE signaling in T2DM.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Magdaleno, F., Blajszczak, C.C., Charles‑Niño, C.L., Guadrón‑Llanos, A.M., Vázquez‑Álvarez, A.O., Miranda‑Díaz, A.G. ... Rincón‑Sánchez, A.R. (2019). Aminoguanidine reduces diabetes‑associated cardiac fibrosis. Experimental and Therapeutic Medicine, 18, 3125-3138. https://doi.org/10.3892/etm.2019.7921
MLA
Magdaleno, F., Blajszczak, C. C., Charles‑Niño, C. L., Guadrón‑Llanos, A. M., Vázquez‑Álvarez, A. O., Miranda‑Díaz, A. G., Nieto, N., Islas‑Carbajal, M. C., Rincón‑Sánchez, A. R."Aminoguanidine reduces diabetes‑associated cardiac fibrosis". Experimental and Therapeutic Medicine 18.4 (2019): 3125-3138.
Chicago
Magdaleno, F., Blajszczak, C. C., Charles‑Niño, C. L., Guadrón‑Llanos, A. M., Vázquez‑Álvarez, A. O., Miranda‑Díaz, A. G., Nieto, N., Islas‑Carbajal, M. C., Rincón‑Sánchez, A. R."Aminoguanidine reduces diabetes‑associated cardiac fibrosis". Experimental and Therapeutic Medicine 18, no. 4 (2019): 3125-3138. https://doi.org/10.3892/etm.2019.7921